JP2023505221A5 - - Google Patents

Info

Publication number
JP2023505221A5
JP2023505221A5 JP2022533441A JP2022533441A JP2023505221A5 JP 2023505221 A5 JP2023505221 A5 JP 2023505221A5 JP 2022533441 A JP2022533441 A JP 2022533441A JP 2022533441 A JP2022533441 A JP 2022533441A JP 2023505221 A5 JP2023505221 A5 JP 2023505221A5
Authority
JP
Japan
Prior art keywords
compound according
compound
alkyl
pharmaceutical composition
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022533441A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023505221A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/063137 external-priority patent/WO2021113528A1/en
Publication of JP2023505221A publication Critical patent/JP2023505221A/ja
Publication of JP2023505221A5 publication Critical patent/JP2023505221A5/ja
Pending legal-status Critical Current

Links

JP2022533441A 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質 Pending JP2023505221A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943728P 2019-12-04 2019-12-04
US62/943,728 2019-12-04
PCT/US2020/063137 WO2021113528A1 (en) 2019-12-04 2020-12-03 Modulators of programmed death-ligand-1 and/or programmed death-ligand-2

Publications (2)

Publication Number Publication Date
JP2023505221A JP2023505221A (ja) 2023-02-08
JP2023505221A5 true JP2023505221A5 (enExample) 2023-11-29

Family

ID=76222302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022533441A Pending JP2023505221A (ja) 2019-12-04 2020-12-03 プログラム死リガンド１および／またはプログラム死リガンド２の調節物質

Country Status (6)

Country Link
US (1) US12098216B2 (enExample)
EP (1) EP4069270A4 (enExample)
JP (1) JP2023505221A (enExample)
AU (1) AU2020396100A1 (enExample)
CA (1) CA3159698A1 (enExample)
WO (1) WO2021113528A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144032A0 (en) 1999-01-13 2002-04-21 Genentech Inc Serine protease inhibitors
GB0514071D0 (en) * 2005-07-07 2005-08-17 Zealand Pharma As N- or C- terminally modified small peptides
ES2748434T3 (es) * 2014-01-10 2020-03-16 Univ Cornell Dipéptidos como inhibidores de inmunoproteasomas humanos
US11046729B2 (en) * 2017-10-26 2021-06-29 Southern Research Institute Dipeptide analogs as TGF-beta inhibitors

Similar Documents

Publication Publication Date Title
JP2021522197A5 (enExample)
EP4499233A1 (en) Kras inhibitors
EP2879677B1 (en) Substituted pyrazolone compounds and methods of use
RU2005118417A (ru) Комбинированное введение индолинона с химиотерапевтическим средством при нарушениях, вызванных клеточной пролиферацией
HRP20100563T1 (hr) Derivati dihidropirazolopirimidinona
JP2018162256A (ja) アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
JP2009514881A5 (enExample)
JP2017521420A5 (enExample)
JP2006508981A5 (enExample)
JP2010519174A5 (enExample)
KR20170090408A (ko) 벤조-헤테로시클릭 화합물 및 이의 적용
HRP20100561T1 (hr) Inhibitori interakcije između mdm2 i p53
JP2023526283A5 (enExample)
JP2011515397A5 (enExample)
RU2016118753A (ru) Производные пиридилкетона, способ их получения и их фармацевтическое применение
WO2012096832A2 (en) Hdac inhibiting derivatives of camptothecin
JP2022537358A5 (enExample)
CN102497862A (zh) 使用ck2调节剂的组合治疗
JP2012518598A5 (enExample)
JPWO2020032105A5 (enExample)
EP2473509A1 (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
AU2024258943A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitor combinations and uses thereof
AU2002259309B2 (en) Antineoplastic combinations
KR20150118102A (ko) Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물
AU2012272646A1 (en) Organic compounds